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Abstract 
Objective S mall prospective studies have identified that children exposed to valproate in 
utero have poorer scores on cognitive testing. We wanted to identify whether children 
exposed to antiepileptic drugs (AEDs) in utero have poorer school performance. 
Methods We used anonymised, linked, routinely collected healthcare records to identify 
children born to mothers with epilepsy. We linked these children to their national attainment 
Key Stage 1 (KS1) tests in mathematics, language and science at the age of 7 and 
compared them with matched children born to mothers without epilepsy, and with the 
national KS1 results. We used the core subject indicator (CSI) as an outcome measure (the 
proportion of children achieving a minimum standard in all subjects) and the results in 
individual subjects. 
Results We identified 440 children born to mothers with epilepsy with available KS1 results. 
Compared with a matched control group, fewer children with mothers being prescribed 
sodium valproate during pregnancy achieved the national minimum standard in CSI (−12.7% 
less than the control group), mathematics (−12.1%), language (−10.4%) and in science 
(−12.2%). Even fewer children with mothers being prescribed multiple AEDs during 
pregnancy achieved a national minimum standard: CSI (by −20.7% less than the control 
group), mathematics (−21.9%), language (−19.3%) and science (−19.4%). We did not 
observe any significant difference in children whose mothers were prescribed 
carbamazepine or were not taking an AED when compared with the control group. 
Conclusions In utero exposure to AEDs in combination, or sodium valproate alone, is 
associated with a significant decrease in attainment in national educational tests for 7-year-
old children compared with both a matched control group and the all-Wales national 
average. These results give further support to the cognitive and developmental effects of in 
utero exposure to sodium valproate as well as multiple AEDs, which should be balanced 
against the need for effective seizure control for women during pregnancy. 
 
Introduction 
Valproate is the most effective drug for treating genetic generalised epilepsy,1 but recent 
prospective psychometric studies have demonstrated cognitive impairment and 
neurodevelopmental disorders in 30%–40% of children exposed to valproate in utero,2 3 as 
well as a significant decrease in IQ.4 5 Women with epilepsy who have satisfactory control 
with valproate and are planning a family therefore have a difficult decision to make. 
In the UK, the Medicines and Healthcare Products Regulatory Agency issued stringent 
guidance for all clinicians prescribing valproate to women of childbearing potential in 2015. 
This guidance was updated in 2017 based on evidence that women are still not aware of the 
risks of taking valproate during pregnancy.6 An International League Against Epilepsy task 
force made seven recommendations, the first of which is “Where possible, valproate should 
be avoided in women of childbearing potential”. Women with epilepsy who are taking 
antiepileptic drugs (AEDs) are presently advised to continue them throughout pregnancy, 
primarily because of the risks of convulsive seizures to the mother and her unborn 
child. 
To be able to counsel mothers adequately about the risks of uncontrolled seizures during 
pregnancy and cognitive outcomes for their children, it is important to know whether the 
psychometric differences demonstrated in research conditions translate to children in the 
community. We aim to investigate the effect of AED exposure in utero on the educational 
attainment of children born to mothers with epilepsy using anonymised, routinely collected 
healthcare records and the results of a standard national educational assessment. 
 
Methods 
Cohort selection 
We used the Secure Anonymous Information Linkage (SAIL) databank7 8 to access 
routinely collected healthcare records and identify women who had been diagnosed with 
epilepsy before becoming pregnant. All studies using SAIL data need independent 
Information Governance Review Panel (IGRP) approval. This study obtained IGRP approval 
(ref 0228). The Research Ethics Service has previously confirmed that SAIL projects using 
anonymised routinely collected data do not require specific NHS research ethics committee 
approval. 
In Wales, every individual is assigned a National Health Service general practitioner (GP). 
SAIL currently contains primary care records for 80% of Welsh GPs corresponding to 77% of 
the Welsh population (approximately 2.3 million people). GPs provide primary healthcare, 
prescribe medication and maintain health records for individuals. GPs will prescribe AEDs 
for people with epilepsy in almost all cases, but the current standard of care is that everyone 
with a suspected seizure is first seen by a ‘specialist’ (neurologist or epileptologist) within 2 
weeks of their first event.9 10 Medication is first prescribed by the specialist at or following 
this visit. A letter with details of the diagnosis and AED prescription is subsequently sent to 
the patient’s GP. 
We defined a person as having a diagnosis of epilepsy if their GP record contained an 
epilepsy diagnosis code as well as a record of repeat AED prescriptions.11–14 Currently, 
seizure type, seizure frequency and AED daily doses are not accurately available from the 
datasets held within SAIL. 
 
Educational assessment in England and Wales 
Between 1999 and 2011, children in Wales were assessed over five Key Stages (KS) 
between 7 and 16 years of age. These tests were a national measure of educational 
achievement of children in Wales and therefore provide a standardised measure of 
educational attainment. Every child is tested in mathematics, language (English or Welsh) 
and science and is awarded a level between 1 (lowest) and 3 (highest). In certain 
circumstances, children may obtain an unclassified or ‘working towards’, meaning that they 
do not achieve the required grade to pass the year. KS1 assessment takes place at the age 
of 7 years. The core subject indicator (CSI) is defined as the proportion of children achieving 
a minimum standard in all three KS1 subjects, that being a level 2 or higher in each subject. 
In 2011, in Wales, the KS1 system for children 5–7 years old was combined with the Early 
Years assessment for children between 3 and 5 years of age and is now called the 
Foundation Phase to assess children between the ages of 3 and 7 years. KS1 for children 
5–7 years old was not combined with earlier years in England and is still used as a standard 
test. We were able to obtain a subset of results from the Welsh Government in the pre-2011 
phase to assess the educational achievement of children in KS1 born to mothers with 
epilepsy. For these children, we linked data from the Department for Children, Education, 
Lifelong Learning and Skills dataset and their corresponding 2003–2008 KS1 results to their 
birth records and their mothers’ GP records in the SAIL databank.15 
 
Education data ascertainment 
Given that KS1 results (taken at the age of 7) were only available within SAIL for the years 
2003–2008 at the time of this study, we searched for women with epilepsy who gave birth 
between 1996 and 2001 and had children who had KS1 results that were accessible within 
SAIL. We divided the mothers into groups based on the AED that they were prescribed 
during pregnancy (including those who were not prescribed an AED) and created a control 
group (with 4:1 matching) matched for maternal age, week of gestational age and 
deprivation at the time of birth. We used the Welsh Index of Multiple Deprivation (WIMD) as 
a measure of deprivation.13 Information on any additional learning support that individual 
children may have had was not available. 
 
Statistical analyses 
We used R V.3.2.0 to conduct the statistical analyses. We used a χ2 significance test to 
compare the KS1 results of each group and performed a conservative Bonferroni correction 
using the ‘p.adjust ()’ function that multiplies the raw P value by the number of independent 
tests and calculated confidence limits using the ‘summaryCE ()’ function from the Rmisc 
package. 
 
Results 
Cohort profile 
We identified 440 children with KS1 results available between 2003 and 2008 who had 
mothers with epilepsy diagnosed before their pregnancy and had GP records within SAIL. 
We defined five groups of mothers prescribed the following AEDs: monotherapy with 
carbamazepine, lamotrigine or sodium valproate, multiple AEDs as well as no AED 
prescription (see online supplementary table 1). Twenty of the 39 mothers (54%) in the 
polytherapy group were prescribed sodium valproate as one of their AEDs. Further details 
on the 15 different combinations of AEDs prescribed in the polytherapy group can be seen in 
online supplementary tables 2 and 3. The numbers for the polytherapy combinations are 
small; we therefore did not perform any analysis on these subgroups, but present results for 
the polytherapy group as a whole. We did, however, analyse educational attainment in the 
polytherapy group when split into those on polytherapy treatment with sodium valproate and 
those on polytherapy treatment without sodium valproate, but we found no significant 
difference between these two groups across any attainment indicator (please see online 
supplementary table 4). Reference data for the control variables (gestational age, maternal 
age and WIMD score) in each group are reported in online supplementary table 1. There 
was no significant difference in the mean of these variables when compared with controls. 
We have included results for all children in Wales in online supplementary table 1 to provide 
context to the KS1 results. Since we have prescription data only, we are unable to comment 
on AED adherence, but we do not expect adherence to differ across different AED 
prescriptions. The proportion of children in each group achieving at least a level 2 in each 
subject is shown in figure 1. 
Children born to mothers with epilepsy being prescribed sodium valproate during pregnancy 
have a lower level of achievement in KS1 tests across all indicators other than language. 
Fewer children exposed to sodium valproate in utero achieve the minimum standard when 
compared with the matched control group by CSI=−12.7% (P=0.035) less than the control 
group, mathematics=− 12.1% (P=0.011), language=−10.4% (P=0.188) and science=−12.2% 
(P≤0.004) (P values are Bonferroni corrected for multiple testing—see the Methods section). 
Children born to mothers with epilepsy being prescribed multiple AEDs during pregnancy 
also have a lower level of achievement across all indicators other than language when 
compared with the matched control group by CSI=−20.7% (P=0.042) less than the matched 
control group, mathematics=−21.9% (P≤0.007), language=−19.3% (P=0.269) and 
science=−19.4% (P=0.010) (P values are Bonferroni corrected for multiple testing—see the 
Methods section). We did not find a significant decrease in attainment in children born to 
mothers with epilepsy who were not prescribed an AED during pregnancy. Excluding 
children with epilepsy and mothers who were recorded as smoking during pregnancy did not 
change the results in terms of significant results. 
 Discussion 
We demonstrate through the analysis of linked data in the SAIL databank that mothers being 
prescribed multiple AEDs and those being prescribed sodium valproate have children with 
significantly poorer attainment in national tests at the age of 7. In contrast, there was no 
difference seen in children exposed to carbamazepine, lamotrigine or mothers who did not 
take drugs during pregnancy; however, we note that the sample size for the lamotrigine 
group is small. Our findings support previous studies that provide consistent evidence that in 
utero exposure to sodium valproate and AEDs in combination are linked to adverse 
neurodevelopmental outcomes. Mothers not prescribed any drug during pregnancy do not 
appear to give birth to children who have decreased educational attainment as compared 
with the control group. This might be expected given both groups are not exposed to AEDs. 
It is also possible that the mothers with epilepsy not taking AEDs have less frequent 
seizures, thus reducing the risks to the unborn child associated with exposure to maternal 
seizures.16 We acknowledge factors such as parental IQ and social and behavioural issues 
can also have an effect on educational outcome and so must be taken into context with the 
results presented in this study. The strength of this study is the ability to select a large cohort 
of 440 children with national test results without major recruitment bias and compare with a 
large control group. We created a control cohort matched on maternal age, gestational age 
and socioeconomic deprivation, but we were unable to control for maternal body weight at 
time of pregnancy. The children born to mothers with epilepsy in this study have an 
increased deprivation score when compared with Welsh children as a whole, as is expected 
given the association with epilepsy and deprivation. 14 Using a standardised national 
assessment as a measure of performance ensures that each child has the opportunity to be 
assessed based on the same curriculum, and as such these results would closer reflect the 
learning experience of children at this age compared with an IQ test. 
 
 
 
  
 
  
The main limitation of this study is not being able to use maternal IQ, as well as other 
maternal factors, such as maternal weight or alcohol consumption during pregnancy, as 
covariates.4 5 Children born to mothers with epilepsy may have other conditions that affect 
their ability to perform in the KS1 tests, and we have not specifically looked for these 
although we have recorded the number of children with epilepsy. We have been unable to 
account for parental style and/or ability in this study, which may influence educational 
attainment. It is also possible that mothers with poorly controlled seizures may have an 
effect on their child’s education in terms of parental support outside of school settings, but 
this information is difficult to ascertain and is not available to any comprehensive standard 
within the SAIL databank. Another limitation of this study is that we are unable to report on 
AED dosage, although other studies have reported significant cognitive impairment even 
at low dosages of sodium valproate. It is possible that the mothers prescribed sodium 
valproate as well as those prescribed multiple AEDs have more severe epilepsy, and this 
may explain the difference in KS1 results. We are currently unable to measure seizure 
frequency/epilepsy severity, identify epilepsy type, or ascertain alcohol and illicit drug use 
accurately from SAIL data. Another factor that could have influenced educational attainment 
is the lack of preconception/ perinatal folic acid prescription, which we were not available to 
ascertain accurately, as this is available without prescription and frequently taken ‘over the 
counter’.  
Although our cohort is large, we do not have sufficient outcomes to look at other AEDs or to 
look at different AED combinations in detail. We were not able to report any results for drugs, 
such as levetiracetam, introduced after the window for pregnancy (1996–2001) that we used 
in this study. This time period was limited by the period that KS1 results were available 
within SAIL (2003–2008). 
Our results support the evidence of many independent studies that have reported cognitive 
impairment of children exposed to sodium valproate in utero. The NEAD study found a 
ninepoint decrease in IQ in children at 3 and 6 years old who were born to mothers taking 
sodium valproate during pregnancy4 5 as well as decreased motor, emotional and 
behavioural/adaptive functioning in children at 3 years old.17 Studies based on the 
UK Epilepsy and Pregnancy Register have found an association between sodium valproate 
and a decrease in cognitive development with early cognitive delay that suggests children 
are at a disadvantage well before school age.18 19 While this study finds a statistically non 
significant trend in language at KS1, other studies have shown decreased language and 
verbal skills at an early infant stage.20–22 
Previous studies have found an association with carbamazepine exposure and cognitive 
impairment, and there are other studies that have found no association between 
carbamazepine exposure and cognitive impairment; our study supports the latter with no 
evidence of decreased educational attainment at school age.23 
While this study highlights the risk of cognitive effects in the children of mothers prescribed 
sodium valproate or multiple AEDs, it is important to acknowledge that some epilepsies are 
difficult to treat without these treatment regimes. Despite this, our results add to the growing 
evidence that in utero exposure to certain AEDs can cause developmental problems in 
children. Women with epilepsy should be informed of this risk and alternative treatment 
regimens should be discussed before their pregnancy with a physician that specialises in 
epilepsy. 
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